bpc 157 clinical trials human BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded The Stable Gastric Pentadecapeptide BPC

Rats receiving the large capsule showed increased glial proliferation, brain swelling, and angiogenesis, while those receiving small doses showed preservation of a large number of tyrosine hydroxylase-positive fibers and a neuroprotective effect on dopamine neurons, indicating that VEGF at low doses can potentially support PD treatment (Yasuhara and Shingo 2005)

A stack addresses multiple aspects simultaneously

Conditions where cellular NAD decline or the beneficial effects of NAD boosting therapy have been described

Both Ozempic (Semaglutide) and Mounjaro (Tirzepatide) are GLP-1 receptor agonists (Mounjaro adds GIP)

Tropomyosin concentration but not formin nucleators mDia1 and mDia3 determines the level of tropomyosin incorporation into actin filaments